6-K ·Filed Aug 26, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed1mo ago SEC0001654954-26-007877
Notable filing: 6-K
Actionable Insight • Neutral

No trading action warranted. This is a routine plan-level notional acquisition by a senior executive with no open-market signal. Monitor next quarterly earnings for fundamental updates on GSK's pipeline and revenue trajectory.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
GSK ▼ -0.68% at T+20d
NEUTRAL call ✗ call lost -0.68% · α vs SPY -1.88% · entry $51.43 → $51.08
Next anchor: T+60d in 7w
Latest observation: T+24 -2.35% FF3 residual α
Entry anchored
Aug 26, 10:37 AM ET
via 1-min bar
T+1d
-2.26%
call -2.26% · α -2.91%
$50.27
settled 5w ago
T+5d
-1.92%
call -1.92% · α -1.80%
$50.44
settled 4w ago
T+20d
-0.68%
call -0.68% · α -1.88%
$51.08
settled 8d ago
T+60d
—
call — · α —
—
in 7w

Price Chart

Loading chart...

Executive Summary

GSK filed a Form 6-K reporting that Maya Martinez-Davis, President US, acquired 9.221 notional American Depositary Shares at $51.78 within her Executive Supplemental Savings Plan account on August 24, 2026. This is a routine, immaterial plan acquisition by a senior executive — not an open-market purchase — and carries no trading signal for the stock.

Key Facts

  • Maya Martinez-Davis, President US, acquired 9.221 notional ADS at $51.78 on 2026-08-24
  • Transaction was within the GSK Executive Supplemental Savings Plan account — not an open-market purchase
  • Total value of the acquisition is approximately $477
  • Filing is a routine PDMR transaction notification with no material financial information

Financial Impact

Approximately $477 total value — immaterial for a $105B market cap company

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007877
Document: 0001654954-26-007877-index-headers.html0001654954-26-007877
Document: 0001654954-26-007877-index.html0001654954-26-007877
Document: 0001654954-26-007877.txt0001654954-26-007877
42 reports for GSK
Performance horizon
69% Hit rate 11 of 16 directional calls best @ T+60▲ +7.85%Jun 16, 2026
Filters
Rows
Reports for GSK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 5/10
$50.01 $50.22▲ +0.42%▼ −0.40%$47.03 (−5.96%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 11, 2026
21d ago
6-K
NEUTRAL ★ 1/10
$48.13 $50.22▲ +4.34%▲ +4.56%$47.03 (−2.29%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 1/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 3/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 6/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 1/10
$51.43 $50.44▼ −1.92%▼ −1.80%$47.03 (−8.56%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$51.78 $50.25▼ −2.95%▼ −3.42%$47.03 (−9.17%)
Showing 10 of 42

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access